<DOC>
	<DOCNO>NCT02734173</DOCNO>
	<brief_summary>There compel data support pursuit research effect HCV antiviral metabolic homeostasis . As rationale justification , experience HIV antiretrovirals clearly demonstrate antiviral medication produce profound change glucose metabolism , lipid profile measure metabolic homeostasis . This establish biological plausibility focus research HCV . The new knowledge create research : 1 . Provide new information metabolic effect Abbvie 3D HCV antiviral regimen . 2 . Provide insight whether metabolic advantage RBV-free compare RBV-containing HCV regimens . This particularly relevant give current uncertainty regard need RBV IFN-free , oral DAA regimen . 3 . Provide insight impact cirrhosis metabolic milieu , HCV antiviral therapy</brief_summary>
	<brief_title>Pilot HCV DAA Metabolism</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>HCV RNA evidence HCV infection Documented history chronic HCV RNA infection Genotype 1 Able provide inform consent Available ongoing followup require &lt; 18 year old Evidence decompensated liver disease HOMA IR &lt; 2.0 HIV seropositivity Chronic HBV/HIV infection Use immune suppress medication Active malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>